WO2003038430A1 - Screening method - Google Patents

Screening method Download PDF

Info

Publication number
WO2003038430A1
WO2003038430A1 PCT/JP2002/011147 JP0211147W WO03038430A1 WO 2003038430 A1 WO2003038430 A1 WO 2003038430A1 JP 0211147 W JP0211147 W JP 0211147W WO 03038430 A1 WO03038430 A1 WO 03038430A1
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
compound
necrosis
inhibitory effect
screening
Prior art date
Application number
PCT/JP2002/011147
Other languages
French (fr)
Japanese (ja)
Inventor
Tohru Mizushima
Ken-Ichi Naruo
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2003038430A1 publication Critical patent/WO2003038430A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

(1) A method of screening a compound having a COX inhibitory effect and a weak effect of inducing necrosis and/or apoptosis, characterized by comprising culturing digestive mucosal cells in the presence of a compound having a COX inhibitory effect and detecting the activity of inducing necrosis and/or apoptosis; (2) a method of screening a compound having a COX inhibitory effect and an effect of inhibiting the induction of necrosis and/or apoptosis, characterized by comprising culturing digestive mucosal cells in the presence of a compound having a COX inhibitory effect and a necrosis inducer or an apoptosis inducer, and detecting the activity of inducing necrosis and/or apoptosis; and (3) a compound, its salt, etc. obtained by the screening method (1) or (2).
PCT/JP2002/011147 2001-10-29 2002-10-28 Screening method WO2003038430A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-330835 2001-10-29
JP2001330835 2001-10-29

Publications (1)

Publication Number Publication Date
WO2003038430A1 true WO2003038430A1 (en) 2003-05-08

Family

ID=19146503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011147 WO2003038430A1 (en) 2001-10-29 2002-10-28 Screening method

Country Status (1)

Country Link
WO (1) WO2003038430A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1194823A (en) * 1997-05-30 1999-04-09 Cell Pathways Inc Identification of compound for suppressing ulcerative lesion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1194823A (en) * 1997-05-30 1999-04-09 Cell Pathways Inc Identification of compound for suppressing ulcerative lesion

Similar Documents

Publication Publication Date Title
ZA200309738B (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same.
WO2004005472A3 (en) Inhibitors of ftsz and uses thereof
MXPA03005960A (en) Novel mixtures of microbial enzymes.
WO2005066151A3 (en) Histone deacetylase inhibitors
MXPA03009562A (en) Methods of treating syndrome x with aliphatic polyamines.
IL158994A0 (en) Ring-type sputtering target
AU2003270883A1 (en) Detection of preselected data
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
AU2003249713A1 (en) 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
ITMI20022704A1 (en) PROCEDURE FOR THE PRODUCTION OF MESITILENE AND DURENE.
WO2003035889A3 (en) Compositions and methods for bacteria detection
WO2003038430A1 (en) Screening method
AU2003257470A1 (en) Detection of microorganisms
WO2003017925A3 (en) Treatment of type i diabetes
ZA200303274B (en) Method of treating shellfish.
WO2004047751A3 (en) Calcilytic compounds
AU2003302326A1 (en) Rapid detection of microorganisms
AU2002366722A1 (en) Method for the detection of the energy and water consumption of dishwashers, and dishwashers
AU2003268483A1 (en) Draft inducer system
GB2334100A8 (en) Chromogenic substrates, media and methods for the detection of salmonella spp.
NO20041295L (en) Tieno (1,3) oxazin-4-ones with lipase inhibitory activity
AP2005003226A0 (en) Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide.
AU2003282314A1 (en) System for regulating the level of an amplified signal in an amplification chain.
ATE362706T1 (en) DEVICE FOR PLATING FOOD, PARTICULARLY MEAT
AU2003273738A1 (en) Method for identifying the enzyme activities of any protein extract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP